Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md., Aug. 9, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended June 30, 2013 and provided a business and clinical update.
“The focus of the second quarter was preparation for the start of several trials, both in the U.S. and internationally, in the second half of the year. We expect to begin our NSI-566 ALS Phase II trial in August or September, at both Emory and the University of Michigan.
Hey, check out all the engineering jobs. Post your resume today!
